The Clarity Pharmaceuticals Ltd (ASX: CU6) share price is in focus today after the company reported a 68% jump in revenue to $8 million, alongside a net loss of $107.2 million for the year ended 30 June 2026.

What did Clarity Pharmaceuticals report?

• Revenue increased 68% to $8.0 million
• Net loss after tax widened to $107.2 million (up 67%)
• Research and development spend rose to $91.1 million
• Liquid assets grew to $178.3 million at year end
• No dividend declared for FY26
• Net tangible assets per share up to 49.9 cents (from 28.1 cents)

What else do investors need to know?

Clarity raised $203 million in fresh capital through a placement at the end of July 2025, strengthening its cash reserves for future clinical trials and commercialisation. The company received a $9.8 million R&D tax incentive refund, highlighting its ongoing investment in Australian radiopharmaceutical research.

The year was marked by significant clinical progress, with flagship prostate and neuroendocrine tumour imaging and therapy candidates advancing through multiple phase II and phase III trials. Manufacturing and supply agreements were expanded to support the anticipated launch of key products.

What did Clarity Pharmaceuticals management say?

Executive Chair Dr Alan Taylor said:

Our strong progress across clinical, regulatory, and manufacturing activities this year lays the foundation for our transition from developer to commercial stage. We remain focused on bringing innovative diagnostic and therapeutic radiopharmaceuticals to patients globally.

What’s next for Clarity Pharmaceuticals?

Clarity is prioritising late-stage clinical trials and regulatory submissions in the US for its core copper-based SAR technology platform. The company will also focus on building its commercial infrastructure, supported by expanded manufacturing capabilities and new executive appointments.

Looking ahead, Clarity remains well funded and plans to progress new studies targeting unmet needs in cancer care, while preparing for product launches in the US and other key markets.

Clarity Pharmaceuticals share price snapshot

Over the past 12 months, Clarity Pharmaceuticals shares have declined 33%, trailing the All Ordinaries Index (ASX: XAO), which is flat over the same period.

View Original Announcement

The post Clarity Pharmaceuticals FY26 earnings: Revenue jumps, losses widen as clinical pipeline progresses appeared first on The Motley Fool Australia.

More reading

• This ASX biotech is tipped to more than double in value
• Clarity Pharmaceuticals reports clinical trial milestones
• Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose
• Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The S&P/ASX 200 Index (ASX: XJO) is losing ground on Thursday, with another wave of selling pushing the market closer to the 9,000-point mark.

At the time of writing, the benchmark is down 0.77% to 9,057 points after touching an intraday low of 9,053 points.

That puts the index at its lowest level in 4 trading days and continues the pullback from the stronger levels seen earlier this month.

There also aren’t many places for investors to hide today, with 144 shares trading lower compared with just 48 moving higher.

So, what’s behind the weakness?

Rate hike concerns are growing

The biggest issue hanging over the market is the changing outlook for interest rates.

Wednesday’s hotter-than-expected inflation figures already had investors reconsidering whether the RBA could raise rates again.

Household spending increased 1.1% in July and was 7% higher than a year earlier, showing Australian consumers are still spending despite higher borrowing costs.

The latest figures have added to concerns that another RBA rate hike could be on the way.

That’s worth watching with the share market still trading close to record highs and valuations are already looking pretty high.

Morgan Stanley has warned that Australian equities are “not priced for a hike”, noting the ASX 200 is trading on a 12-month forward P/E ratio of 18.1 times.

With another rate hike now a real possibility, investors are becoming more cautious after the market’s run towards record levels.

Most sectors are moving lower

The weakness is spread across most sectors, but several large companies are doing plenty of damage to the index.

BHP Group Ltd (ASX: BHP) shares are down 0.95% to $66.76, while fellow heavyweight Commonwealth Bank of Australia (ASX: CBA) shares are 0.15% lower at $155.22.

Wesfarmers Ltd (ASX: WES) shares have dropped 1.36% to $82.14, while Woolworths Group Ltd (ASX: WOW) shares are down 3.21% to $38.89.

Property shares are also weaker, with Goodman Group (ASX: GMG) down 1.06% to $27.92.

Nonetheless, there are still a few pockets of strength.

Qantas Airways Ltd (ASX: QAN) shares are up 4.39% to $9.63 following its FY26 result, while CSL Ltd (ASX: CSL) shares are 0.44% higher at $173.20.

Foolish takeaway

The ASX 200 is now sitting less than 60 points above the psychological 9,000-point mark, so that level will be worth watching if the selling continues.

Much will depend on whether concerns around another rate hike ease or build further in the lead-up to the RBA’s September meeting.

The post Why is the ASX 200 falling to a 4-day low today? appeared first on The Motley Fool Australia.

More reading

• Do leading brokers rate Woolworths shares as a buy following its results?
• Should I buy CSL shares before the end of August?
• Another RBA interest rate hike could be just weeks away. Here’s what the big banks think
• Where I’d invest $10,000 in ASX shares in September
• Qantas shares jump 4% today: Is this the start of a rebound?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goodman Group, and Wesfarmers. The Motley Fool Australia has recommended BHP Group, CSL, Goodman Group, and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Woolworths Group Ltd (ASX: WOW) shares are under pressure on Thursday.

In afternoon trade, the supermarket giant’s shares are down 3% to $38.96.

Is this a buying opportunity for investors? Let’s see what two leading brokers are saying about the company following its results release this week.

What are brokers saying?

Bell Potter was pleased with the company’s performance in FY 2026, noting that its net profit was ahead of expectations. It said:

WOW reported a FY26 underlying NPAT ahead of our expectations at $1,599m (BPe $1,511m and VA $1,553m). Key operating statistics of the result included: Operating results: Revenue of $71,539m was up +4% YoY (vs. BPe $71,431m and VA of $71,628m). EBITDA of $6,089m was up +7% YOY (vs. BPe of $6,123m and VA of $6,133m). Underlying NPAT of $1,599m was up +15% YOY (vs. BPe of $1,511m and VA of $1,553m). Group gross margin was up +12bps YoY and CODB was down -13bps YoY.

In response to the result and outlook commentary, the broker has made a material increase to its near-term estimates. It revealed that “NPAT changes are +16% in FY27e and +12% in FY28e.”

This has led to Bell Potter increasing its price target on Woolworths shares to $42.35 (from $35.50).

However, with potential upside now just under 9%, that isn’t quite enough for a buy rating, and the broker has held firm with its hold recommendation. It commented:

There has been a clear acceleration in the topline of the Australian food business in recent quarters (>200bp outperformance since 2Q26) and material recovery in the Big W business driving a return to growth at WOW. Continued growth in eCommerce sales in the Australian Food business (>17% in penetration in 4Q26), A material uplift in digital platform traffic (+13% YoY in 4Q26) and growth in active rewards members (to 10.8m users) are all encouraging signals for investments in online capability and customer capture. In the near term, WOW should also benefit from reduced supply chain implementation costs ($113m expense in FY26).

What else are brokers saying?

The team at Morgans is a little more positive on Woolworths shares. Following a review of the results, the broker has retained its accumulate rating (between buy and hold) with an improved price target of $43.50. This implies potential upside of almost 12% for investors over the next 12 months.

Commenting on its recommendation, Morgans said:

WOW’s FY26 result was slightly better than expected. Australian Food earnings were in line with our forecast, while Australian B2B and W Living exceeded expectations. NZ Food was softer following a challenging 2H26. Encouragingly, Australian Food sales momentum has continued into early FY27, supported by the popular Disney Ooshies collectibles campaign. 

Excluding this benefit, sales growth remained solid, indicating the underlying business continues to perform well. We adjust FY27/28/29F underlying EBIT by +2%/+2%+4%. Our target price increases to $43.50 (from $37.30), reflecting changes to earnings forecasts and a higher valuation multiple. The multiple expansion reflects continued positive momentum in the core Australian Food segment, our increased confidence that this sales growth can be sustained, and improved execution. We maintain our ACCUMULATE rating.

The post Do leading brokers rate Woolworths shares as a buy following its results? appeared first on The Motley Fool Australia.

More reading

• Why is the ASX 200 falling to a 4-day low today?
• 3 ASX 200 dividend shares that just hiked their payouts
• South32, Woolworths, BHP shares reach 52-week high: Buy, sell or hold?
• Everything you need to know about the Woolworths dividend
• Why Woolworths, Domino’s and DroneShield shares are turning heads on Wednesday

Motley Fool contributor James Mickleboro has positions in Walt Disney and Woolworths Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Walt Disney. The Motley Fool Australia has recommended Walt Disney. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.